Effect of Xolair on Airway Hyperresponsiveness

Status Active, not recruiting

Clinical Trial Summary

The purpose of this study is to determine if Xolair can reduce the abnormal increase in limitation to airflow in patients with asthma in a relatively short time period. Another purpose is to determine if Xolair will decrease the amount of inflammation in the lungs of an asthmatic patient in the same time period.

Clinical Trial Description

Xolair, a recombinant humanized monoclonal anti-IgE antibody, has been studied extensively and proven efficacious in the treatment of asthma and other allergic disorders. In moderate to severe allergic asthmatic patients, Xolair reduced asthma exacerbations and improved symptoms. However, there is limited data on the effects of Xolair on airway hyperreactivity, an important component of asthma. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00208234
Study type	Interventional
Source	Creighton University
Contact
Status	Active, not recruiting
Phase	Phase 4
Start date	January 2004
Completion date	September 2011

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03850626` - Validation of Combined Symptom Medication Score (cSMS) in Allergic Patients
Completed	`NCT02911688` - Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure	Phase 2
Active, not recruiting	`NCT01776177` - The REALITY Study - a Real-life Long-term Analysis of Xolair Therapy	N/A
Completed	`NCT00485576` - Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma	Phase 2
Completed	`NCT00515775` - Influence of a Inhaled Corticosteroid Therapy Versus Corticosteroid + LABA Therapy on the FeNO of Asthmatic Children	N/A
Completed	`NCT00736801` - Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma	N/A
Completed	`NCT04259164` - Anti-inflammatory Effects Glycopyrronium	Phase 3
Active, not recruiting	`NCT04619017` - Airway Immune Response to Allergens (Use Lay Language Here)	Phase 1
Completed	`NCT01699594` - Change in Airway Responsiveness After Allergen Exposure	N/A
Completed	`NCT01353755` - 2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma	Phase 3
Completed	`NCT00999466` - The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen	Phase 2
Completed	`NCT00434434` - A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma	Phase 2
Completed	`NCT00492076` - Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma	Phase 4
Completed	`NCT00829179` - Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma	Phase 3
Completed	`NCT00490425` - Prevention of Asthma and Allergy by Probiotic Lactobacillus GG	Phase 4
Recruiting	`NCT04542902` - Non-coding RNAs Analysis of Eosinophil Subtypes in Asthma	N/A
Recruiting	`NCT04109534` - Effect of a Dietary Fatty Acid Supplementation on Symptoms and Bronchial Inflammation in Patients With Asthma	N/A
Active, not recruiting	`NCT05186025` - Tyrosine Allergoid Paediatric and Adult Study
Withdrawn	`NCT03307278` - House Dust Mite Induced Inflammasome Activation on Corticosteroid Resistance	N/A
Enrolling by invitation	`NCT06151938` - Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis